Hvsen Biotechnology Co., Ltd.

SZSE:300871 株式レポート

時価総額:CN¥1.8b

Hvsen Biotechnology 過去の業績

過去 基準チェック /06

Hvsen Biotechnology's earnings have been declining at an average annual rate of -50.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 9.8% per year.

主要情報

-50.4%

収益成長率

-53.7%

EPS成長率

Pharmaceuticals 業界の成長10.9%
収益成長率9.8%
株主資本利益率-3.2%
ネット・マージン-4.1%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Sep 30
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate

Aug 21
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate

Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper

Jun 05
Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

Mar 29
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

収支内訳

Hvsen Biotechnology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

SZSE:300871 収益、費用、利益 ( )CNY Millions
日付収益収益G+A経費研究開発費
30 Sep 241,121-4616052
30 Jun 241,007-5115552
31 Mar 24996-1415550
31 Dec 231,0201715545
30 Sep 231,0434112945
30 Jun 231,0756212242
31 Mar 231,0486611540
01 Jan 231,0235311340
30 Sep 22922408445
30 Jun 22857388049
31 Mar 22888718351
01 Jan 229961338147
30 Sep 211,02717310441
30 Jun 211,02619910534
31 Mar 219561889931
31 Dec 207771509128
30 Sep 206551307922
31 Dec 19427696421
31 Dec 18422717920
31 Dec 17400887818
31 Dec 16258496313

質の高い収益: 300871 is currently unprofitable.

利益率の向上: 300871 is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: 300871 is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.

成長の加速: Unable to compare 300871's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: 300871 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).


株主資本利益率

高いROE: 300871 has a negative Return on Equity (-3.21%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘